Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis.

Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jun 2006Cited by 158 (Europe PMC)

PMID16753016DOI10.1359/jbmr.060314PepBankPUB-16753016

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialMechanism
In osteoporotic postmenopausal women, modeling bone formation at quiescent surfaces occurred only after teriparatide, not placebo.
In plain wordsIn women with osteoporosis, bone formation on inactive surfaces occurred only with teriparatide, not placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseModeling bone formation at quiescent surfaces
Study
n = 55
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 or 40 microg · 12-24 monthsAs given in this study (human).
Source sentences
Summary
We report direct evidence that modeling bone formation at quiescent surfaces was present only in teriparatide-treated patients and bone formation at remodeling sites was higher with teriparatide than placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Transiliac bone biopsies were obtained from 55 postmenopausal women treated with teriparatide 20 or 40 microg or placebo for 12-24 months (median, 19.8 months) in the Fracture Prevention Trial.
Report a problemFND-1675301601
02HumanNon-randomized trialMechanism
In osteoporotic postmenopausal women, bone formation at remodeling sites was higher with teriparatide than placebo.
In plain wordsIn women with osteoporosis, bone formation at remodeling sites was higher with teriparatide than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone formation at remodeling sites
Study
n = 55
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 or 40 microg · 12-24 monthsAs given in this study (human).
Source sentences
Summary
We report direct evidence that modeling bone formation at quiescent surfaces was present only in teriparatide-treated patients and bone formation at remodeling sites was higher with teriparatide than placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Transiliac bone biopsies were obtained from 55 postmenopausal women treated with teriparatide 20 or 40 microg or placebo for 12-24 months (median, 19.8 months) in the Fracture Prevention Trial.
Report a problemFND-1675301602
03HumanNon-randomized trialMechanism
In osteoporotic postmenopausal women, modeling and mixed remodeling/modeling trabecular hemiosteons showed a dose-dependent relationship with teriparatide.
In plain wordsIn women with osteoporosis, the reported modeling and mixed bone formation pattern depended on teriparatide dose.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedModeling and mixed remodeling/modeling trabecular hemiosteons dose relationship
Study
n: not reported in source
Comparator
Teriparatide doses
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 or 40 microg · 12-24 monthsAs given in this study (human).
Source sentences
Summary
A dose-dependent relationship was observed in modeling and mixed remodeling/modeling trabecular hemiosteons.
1 context sentence(design, population, supporting numbers)
Summary · context
Transiliac bone biopsies were obtained from 55 postmenopausal women treated with teriparatide 20 or 40 microg or placebo for 12-24 months (median, 19.8 months) in the Fracture Prevention Trial.
Report a problemFND-1675301603
04HumanNon-randomized trialMechanism
In osteoporotic postmenopausal women, trabecular hemiosteon wall thickness was higher with teriparatide 20 microg than placebo.
In plain wordsIn women with osteoporosis, teriparatide 20 microg increased trabecular bone wall thickness compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular hemiosteon wall thickness at 20 microg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg · 12-24 monthsAs given in this study (human).
Source sentences
Summary
Trabecular and endosteal hemiosteon mean wall thicknesses were significantly higher in both teriparatide groups than in placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Transiliac bone biopsies were obtained from 55 postmenopausal women treated with teriparatide 20 or 40 microg or placebo for 12-24 months (median, 19.8 months) in the Fracture Prevention Trial.
Report a problemFND-1675301604
05HumanNon-randomized trialMechanism
In osteoporotic postmenopausal women, trabecular hemiosteon wall thickness was higher with teriparatide 40 microg than placebo.
In plain wordsIn women with osteoporosis, teriparatide 40 microg increased trabecular bone wall thickness compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular hemiosteon wall thickness at 40 microg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg · 12-24 monthsAs given in this study (human).
Source sentences
Summary
Trabecular and endosteal hemiosteon mean wall thicknesses were significantly higher in both teriparatide groups than in placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Transiliac bone biopsies were obtained from 55 postmenopausal women treated with teriparatide 20 or 40 microg or placebo for 12-24 months (median, 19.8 months) in the Fracture Prevention Trial.
Report a problemFND-1675301605
06HumanNon-randomized trialMechanism
In osteoporotic postmenopausal women, endosteal hemiosteon wall thickness was higher with teriparatide 20 microg than placebo.
In plain wordsIn women with osteoporosis, teriparatide 20 microg increased endosteal bone wall thickness compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEndosteal hemiosteon wall thickness at 20 microg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg · 12-24 monthsAs given in this study (human).
Source sentences
Summary
Trabecular and endosteal hemiosteon mean wall thicknesses were significantly higher in both teriparatide groups than in placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Transiliac bone biopsies were obtained from 55 postmenopausal women treated with teriparatide 20 or 40 microg or placebo for 12-24 months (median, 19.8 months) in the Fracture Prevention Trial.
Report a problemFND-1675301606
07HumanNon-randomized trialMechanism
In osteoporotic postmenopausal women, endosteal hemiosteon wall thickness was higher with teriparatide 40 microg than placebo.
In plain wordsIn women with osteoporosis, teriparatide 40 microg increased endosteal bone wall thickness compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEndosteal hemiosteon wall thickness at 40 microg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg · 12-24 monthsAs given in this study (human).
Source sentences
Summary
Trabecular and endosteal hemiosteon mean wall thicknesses were significantly higher in both teriparatide groups than in placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Transiliac bone biopsies were obtained from 55 postmenopausal women treated with teriparatide 20 or 40 microg or placebo for 12-24 months (median, 19.8 months) in the Fracture Prevention Trial.
Report a problemFND-1675301607
08HumanNon-randomized trialMechanism
In osteoporotic postmenopausal women, IGF-II immunoreactive staining showed a teriparatide dose-dependent relationship at all studied bone envelopes.
In plain wordsIn women with osteoporosis, bone IGF-II staining depended on teriparatide dose.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedIGF-II immunoreactive staining dose relationship
Study
n: not reported in source
Comparator
Teriparatide doses
Outcome group
Growth hormone and IGF-1 · Musculoskeletal
Studied dose
20 or 40 microg · 12-24 monthsAs given in this study (human).
Source sentences
Summary
There was a dose-dependent relationship in IGF-II immunoreactive staining at all bone envelopes studied.
1 context sentence(design, population, supporting numbers)
Summary · context
Transiliac bone biopsies were obtained from 55 postmenopausal women treated with teriparatide 20 or 40 microg or placebo for 12-24 months (median, 19.8 months) in the Fracture Prevention Trial.
Report a problemFND-1675301608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.